006280.KS KSC
GC Biopharma Corp.
1W: +2.0%
1M: -1.8%
3M: +1.4%
YTD: -25.6%
1Y: -6.5%
3Y: +13.3%
5Y: -60.5%
₩125,800.00 ($93.54)
-3500.00 (-2.71%)
Weekly Expected Move ±3.9%
₩115884
₩120842
₩125800
₩130758
₩135716
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$99.5B
+286.1% ▲
5Y CAGR: +22.6%
Capital Expenditures
$72.4B
-70.7% ▼
5Y CAGR: -6.5%
Free Cash Flow
$27.1B
+128.3% ▲
Dividends Paid
$18.8B
+3.6% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
$26.8B
+198.8% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $136.9B | $69.4B | -$26.6B | -$42.6B | -$4.7B |
| Depreciation & Amort. | $55.9B | $65.1B | $75.6B | $81.0B | $87.7B |
| Stock-Based Comp. | $0 | $0 | $0 | $0 | $0 |
| Change in Working Capital | -$19.0B | -$8.9B | -$100.3B | -$144.1B | -$25.3B |
| Other Non-Cash Items | -$47.9B | -$6.5B | $45.9B | $52.2B | $41.8B |
| Operating Cash Flow | $126.0B | $119.2B | -$5.5B | -$53.5B | $99.5B |
| — Investing Activities — | |||||
| Capital Expenditures | -$123.5B | -$94.7B | -$126.0B | -$32.0B | -$105.3B |
| Acquisitions (Net) | -$61.4B | -$107.3B | -$17.2B | -$5.8B | -$60.0B |
| Investment Purchases | -$5.8B | -$48.0B | -$49.2B | -$52.1B | -$114.6B |
| Investment Sales | $50.2B | $49.9B | $41.0B | $33.9B | $87.8B |
| Other Investing | $8.5B | -$5.2B | $1.2B | -$11.9B | $5.5B |
| Investing Cash Flow | -$132.1B | -$205.3B | -$150.2B | -$67.9B | -$186.7B |
| — Financing Activities — | |||||
| Net Debt Issuance | -$9.3B | -$12.0B | $133.0B | $121.7B | $139.4B |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | -$18.5B | -$24.0B | -$24.8B | -$19.5B | -$18.8B |
| Other Financing | -$13.5B | $33.5B | -$7.7B | -$8.3B | -$9.2B |
| Financing Cash Flow | -$41.3B | -$2.5B | $100.5B | $93.8B | $111.4B |
| Net Change in Cash | -$46.2B | -$80.7B | -$55.7B | -$27.1B | $26.8B |
| Cash End of Period | $186.1B | $105.4B | $49.7B | $22.6B | $49.4B |
| Free Cash Flow | $2.4B | $24.5B | -$131.5B | -$95.9B | $27.1B |